Stoke Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 31.64, 49.93, 126.57, 329.19, 539.43 ], "ebit_estimate": [ -223.81, -230.58, -162.41, 13.67, 219.92 ], "ebitda_estimate": [ -200.52, -204.47, -87.23, 173.71, 381.14 ], "net_income_estimate": [ -210.31, -217.15, -141.81, 39.12, 216.85 ], "per_share_eps_estimate": [ -3.32, -3.18, -1.88, 0.66, 2.9 ], "eps_nri_estimate": [ -3.29, -3.17, -1.88, 0.66, 2.9 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 4.28, 3.92, 3.23, 3.55, 7.19 ], "pretax_income_estimate": [ -210.31, -220.62, -143.24, 43.08, 230.56 ], "operating_cash_flow_per_share_estimate": [ -3, -2.56, -0.55, 0.51, 3.98 ], "roa_estimate": [ -49.1, -43.6, null, null, null ], "roe_estimate": [ -64.6, -75.6, -35.4, -7.2, 57.4 ], "gross_margin_estimate": [ 100, 100, 87.56, 89, 87.78 ], "operating_cash_flow_estimate": [ -189.19, -161.44, -34.69, 32.16, 251 ], "pettm_estimate": [ 0, 0, 0, 47.26, 10.82 ], "long_term_growth_rate_mean": -127.4, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -127.3, "future_eps_nri_estimate_growth": -127.4, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -86.37, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -148.62, "future_pretax_income_estimate_growth": -149.76, "future_book_value_per_share_estimate_growth": -17.61, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -128.62, "future_gross_margin_estimate_growth": -3.91, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 6.04, 6.3, 7.41, 7.5, 7.5, 7.5, 7.5 ], "ebit_estimate": [ -54.96, -56.35, -59.66, -62.21, -64.59, -62.9, -60.13 ], "ebitda_estimate": [ -49.82, -51, -50.95, -45.88, -49.33, -52.26, -54.16 ], "net_income_estimate": [ -51.38, -53.09, -56.53, -58.19, -60.4, -59.67, -57.04 ], "per_share_eps_estimate": [ -0.79, -0.84, -0.89, -0.93, -0.95, -0.87, -0.81 ], "eps_nri_estimate": [ -0.78, -0.83, -0.89, -0.91, -0.92, -0.87, -0.83 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 5.62, 4.95, 4.27, null, null, null, null ], "pretax_income_estimate": [ -51.38, -53.09, -56.53, -58.67, -61.29, -59.97, -56.13 ], "operating_cash_flow_per_share_estimate": [ -0.66, -0.68, -0.7, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 100, 100, 100 ], "operating_cash_flow_estimate": [ -41.62, -42.88, -44.15, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -127.4, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -127.3, "future_eps_nri_estimate_growth": -127.4, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -86.37, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -148.62, "future_pretax_income_estimate_growth": -149.76, "future_book_value_per_share_estimate_growth": -17.61, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -128.62, "future_gross_margin_estimate_growth": -3.91, "future_operating_cash_flow_per_share_estimate_growth": null }